tag:blogger.com,1999:blog-16774010.post5767620152077790635..comments2024-01-25T17:58:34.297-05:00Comments on Scott's Web Log: Inhalable Insulin May Be A 'Flop'Scott Shttp://www.blogger.com/profile/03286529314567223617noreply@blogger.comBlogger5125tag:blogger.com,1999:blog-16774010.post-79081138234011244072006-11-11T13:50:00.000-05:002006-11-11T13:50:00.000-05:00You're right in that Lilly has been making and sel...You're right in that Lilly has been making and selling insulin since the discovery in 1922. Pfizer has no experience manufacturing insulin, and obviously, none merchandising it either!Scott Shttps://www.blogger.com/profile/03286529314567223617noreply@blogger.comtag:blogger.com,1999:blog-16774010.post-23687683177509595122006-11-11T11:13:00.000-05:002006-11-11T11:13:00.000-05:00The difference between Novo and Lilly and Pfizzer ...The difference between Novo and Lilly and Pfizzer is that those companies have been making insulin for years.Christinehttps://www.blogger.com/profile/13564731989568599206noreply@blogger.comtag:blogger.com,1999:blog-16774010.post-4262555666316521642006-11-06T14:44:00.000-05:002006-11-06T14:44:00.000-05:00The important element to realize is that type 2 is...The important element to realize is that type 2 is caused by a RELATIVE insulin deficiency (as opposed to the ABSOLUTE insulin deficiency exhibited in type 1 diabetes). Regardless of the absolute number of users, insulin is usually part of the problem rather than the solution to the problem for most type 2 patients. There is already a wide body of scientific and medical evidence to substantiate that hyperinsulinemia (excessive insulin) seen in type 2 patients contributes towards accelerating microvascular and cardiovascular damage. Repackaging it may make insulin more appealing, but it does little to address the core problem of insulin resistance. It is for that reason that I doubt insulin will ever be the first treatment choice for endocrinologists treating patients with type 2 diabetes. As for those of us with type 1, I believe Pfizer made a HUGE mistake in abandoning the worldwide standard of measure (the unit) in favor of milligrams, making it tough if not impossible to translate dosages and requiring doctors and CDEs to prescribe different dosage ratios for Exubera vs. all other forms of insulin. I believe Novo Nordisk and Lilly will not make the same mistake when their products finally launch, which may prove to be the last nail in Exubera's coffin.Scott Shttps://www.blogger.com/profile/03286529314567223617noreply@blogger.comtag:blogger.com,1999:blog-16774010.post-48453309681065195082006-11-06T11:45:00.000-05:002006-11-06T11:45:00.000-05:00The Market for Type 2 Diabetes(Insulin Resistant D...The Market for Type 2 Diabetes(Insulin Resistant Disease) far outweighs the one for T1DM, which is why so many pharmaceuticals that are beneficial to IRD exists. I have never been a "big fan" of inhalable insulin for many reasons including the possibility of respiratory problems. However, I am very interested in the buccal mucosa delivery of insulin which Geberex has developed and is being used/tested in Ecuador. Since the insulin does not enter the Lungs, the risk of Respiratory damage is absent. Theoretically, I see no reason why this cannot be used in T1DM as well as IRD as stated by the manufacturer:<br />Generex's flagship product, Generex Oral-lyn™, is an oral insulin spray for the treatment of diabetes.<br /><br />Generex Oral-lyn™ is a liquid formulation of regular human insulin that is delivered to the buccal mucosa by way of the RapidMist™ device,where absorption is limited to the mouth with no entry into the lungs. The rich vascularity of the buccal mucosa allows for much faster absorption of insulin and a shorter total duration of activity which makes Generex Oral-lyn™ an ideal prandial insulin as it can be conveniently administered immediately prior to meals with little prospect of hypoglycemia. Generex Oral-lyn™ can be used as a preventative pharmacologic agent by people with pre-diabetes to delay the onset of diabetes and by patients with type-2 diabetes to delay the onset of insulin dependence and the complications associated with diabetes.BetterCellhttps://www.blogger.com/profile/13667917240368089110noreply@blogger.comtag:blogger.com,1999:blog-16774010.post-681029004166693962006-11-03T18:12:00.000-05:002006-11-03T18:12:00.000-05:00"According to the report...patients would still ha..."According to the report...patients would still have to put up with the usual disadvantages of insulin therapy including...the need to adhere to a restrictive meal-dependent administration routine."<br /><br />Actually, I think a lot of the problem is that insulin in and of itself does not always mean a strict meal schedule, but inhaled insulin does. You can pump to cover carbs, you can shoot to cover carbs, you can't yet inhale to cover carbs because it's just not that precise yet.Christinehttps://www.blogger.com/profile/13564731989568599206noreply@blogger.com